GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » Tax Expense

Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Tax Expense : $0.54 Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Bellevue Life Sciences Acquisition Tax Expense?

Bellevue Life Sciences Acquisition's tax expense for the months ended in Dec. 2023 was $0.15 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.54 Mil.


Bellevue Life Sciences Acquisition Tax Expense Historical Data

The historical data trend for Bellevue Life Sciences Acquisition's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellevue Life Sciences Acquisition Tax Expense Chart

Bellevue Life Sciences Acquisition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Tax Expense
- - - 0.54

Bellevue Life Sciences Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - 0.03 0.23 0.13 0.15

Bellevue Life Sciences Acquisition Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bellevue Life Sciences Acquisition  (NAS:BLAC) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Bellevue Life Sciences Acquisition Tax Expense Related Terms

Thank you for viewing the detailed overview of Bellevue Life Sciences Acquisition's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
10900 NE 4th Street, Suite 2300, Bellevue, WA, USA, 98004
Website
Bellevue Life Sciences Acquisition Corp is a blank check company.
Executives
David Jin Yoo officer: Chief Financial Officer (135-270) 7TH FLOOR, SOFTFORUM B/D., 545-7 DOGOKDONG, GANGNAM, SEOUL M5 135-170
Kuk Hyoun Hwang director, 10 percent owner, officer: Chief Executive Officer 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Bellevue Global Life Science Investors Llc 10 percent owner 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Steven Reed other: Director Nominee 2843-122 PL. N.E., BELLEVUE WA 98005
In Chul Chung other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Hosun Euh other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jin Whan Park other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jun Chul Whang director 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Rad Roberts other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004